Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-16
2008-08-26
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S122000
Reexamination Certificate
active
07417054
ABSTRACT:
Certain naphthyridine compounds are histamine H3receptor and serotonin transporter modulators useful in the treatment of histamine H3receptor- and serotonin-mediated diseases.
REFERENCES:
patent: 4113869 (1978-09-01), Gardner
patent: 2006/0194837 (2006-08-01), Carruthers
patent: 0978512 (2000-02-01), None
patent: 1113007 (2001-07-01), None
patent: 1335261 (1973-10-01), None
patent: 9640142 (1996-12-01), None
patent: WO 01/32624 (2001-05-01), None
patent: WO 2005/111036 (2005-11-01), None
PCT Search Report for PCT/US2006/023788 dated Nov. 15, 2006.
U.S. Appl. No. 11/424,734, filed Jun. 16, 2006, Apodaca.
Alves-Rodrigues, A. et al. Pharmacological Characterisation of the Histamine H3Receptor in the Rat Hippocampus.Brain Res.1998, 788(1-2), 179-186.
Arrang, J.-M. et al. Auto-Inhibition of Brain Histamine Release by a Novel Class (H3) of Histamine Receptor.Nature(London) 1983, 302(5911), 832-837.
Berge, S.M. et al. Pharmaceutical Salts. J. Pharm. Sci., 1977, 66:1-19.
Blandizzi, C. et al. Histamine H3Receptors Mediate Inhibition of Noradrenaline Release from Intestinal Symphathetic Nerves.Br. J. Pharmacol.2000, 129(7), 1387-1396.
Bonnet, U. Moclobemide: Evolution, Pharmacodynamic, and Pharmacokinetic Properties.CNS Drug Rev.2002, 8(3), 283-308.
Chen, Z. Effect of histamine H3-receptor antagonist clobenpropit on spatial memory of radial maze performance in rats.Acta Pharmacol. Sin.2000, 21(10), 905-910.
Cheng, Y-C et al.: Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction*. Biochemical Pharmacology, vol. 22 (1973), 3099-3108.
Darmani, N.A. and S.L. Reeves. The Mechanisms by which the Selective 5-HT1AReceptor Antagonist S-(+)UH 301 Produces Head-Twitches in Mice.Pharmacol., Biochem. Behav.1996, 55(1), 1-10.
Fink, K. et al. Involvement of Presynaptic H3Receptors in the Inhibitory Effect of Histamine on Serotonin Release in the Rat Brain Cortex.Naunyn-Schmiedeberg's Arch. Pharmacol.1990, 342(5), 513-519.
Fox, G.B. et al. Effects of Histamine H3Receptor Ligands GT-2331 and Ciproxifan in a Repeated Acquisition Avoidance Response in the Spontaneously Hypertensive Rat Pup.Behav. Brain Res.2002, 131(1-2), 151-161.
Fox, G.B. et al. Differential in Vivo Effects of H3Receptor Ligands in a New Mouse Dipsogenia Model.Pharmacol., Biochem. Behav.2002, 72, 741-750.
Griffiths, R.I. et al. Medical Resource Use and Cost of Venlaxafine or Tricyclic Antidepressant Therapy.Pharmacoeconomics1999, 15(5), 495-505.
Hatta, E. et al. Activation of Histamine H3Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Infarction.J. Pharmacol. Exp. Ther.1997, 283(2), 494-500.
Hill, S.J. et al. International Union of Pharmacology. XIII. Classification of Histamine Receptors.Pharmacol. Rev.1997, 49(3), 253-278.
Kelly, S.A. et al.: A convergent approach to huperzine A and analogues. Org. Biomol. Chem. 2003, 1, 2865-2876.
Kraly, F.S. et al. H1, H2, and H3Receptors Contribute to Drinking Elicited by Exogenous Histamine and Eating in Rats.Pharmacol., Biochem. Behav.1996, 53(2), 347-354.
Laitinen, K.S.M. et al. Endogenous Serotonin Modulates Histamine Release in the Hypothalamus as Measured by in Vivo Microdialysis.Eur. J. Pharmacol.1995, 285(2), 159-164.
Lamberti, C. et al. Antidepressant-like Effects of Endogenous Histamine and of Two Histamine H1Receptor Agonists in the Mouse Forced Swim Test.Br. J. Pharmacol.1998, 123(7), 1331-1336.
Leurs, R. et al. Histamine Homologues Discriminating between Two Functional H3Receptor Assays. Evidence for H3Receptor Homogeneity?J. Pharmacol. Exp. Ther.1996, 276(3), 1009-1015.
Lin, J.S. et al. Involvement of Histaminergic Neurons in Arousal Mechanisms Demonstrated with H3-Receptor Ligands in the Cat.Brain Res.1990, 523(2), 325-330.
Lovenberg, T.W. et al. Cloning and Functional Expression of the Human Histamine H3Receptor.Molec. Pharmacol.1999, 55(6), 1101-1107.
Lovenberg, T.W. Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. 2000, 293, 771-778.
Maryanoff, B.E. et al.: Pyrroloisoquinoline Antidepressants. 2. In-Depth Exploration of Structure-Activity Relationships. J. Med. Chem., vol. 30(8) (1987), 1433-1454. XP000941930.
Maryanoff, B.E. et al.: Pyrroloisequinoline Antidepressants. 3. A Focus on Serotonin. J. Med. Chem, vol. 33 (1990), 2793-2797. XP002398543.
Menza, M.A. et al. Modafinil Augmentation of Antidepressant Treatment in Depression.J. Clin. Psych.2000, 61(5), 378-381.
Miyazaki, S. et al. Effects of Thioperamide on the cholinergic system and the step-through passive avoidance test in mice.Meth. Find. Exp. Clin. Pharmacol.1995, 17(10), 653-658.
Miyazaki, S. et al. Effects of Thioperamide, A Histamine H3-Receptor Antagonist, on a Scopolamine-Induced Learning Deficit Using an Elevated Plus-Maze Test in Mice.Life Sci.1995, 57(23), 2137-2144.
Monti, J.M. et al. Effects of Selective Activation or Blockade of the Histamine H3Receptor on Sleep and Wakefulness.Eur. J. Pharmacol.1991, 205(3), 283-287.
Monti, J.M. et al. Sleep and Waking during Actue Histamine H3Agonist BP 2.94 or H3 Antagonist Carboperamide (MR 16155) Administration in Rats.Neuropsychopharmacology1996, 15(1), 31-35.
Olver, J.S. et al. Third Generation Anti-depressants: Do They Offer Advantages over the SSRIs?CNS Drugs2001, 15(12), 941-954.
Orsetti, M. et al. Histamine H3-Receptor Antagonism Improves Memory Retention and Reverses the Cognitive Deficit Induced by Scopolamine in a Two-Trial Place Recognition Task.Behav. Brain Res.2001, 124(2), 235-242.
Parent, M. et al. Analysis of Amino Acids and Catecholamines, 5-Hydroxytryptamine and Their Metabolites in Brain Areas in the Rat Using in Vivo Microdialysis. Methods 2001, 23(1), 11-20.
Perez-Garcia, C. et al. Effects of Histamine H3Receptor Ligands in Experimental Models of Anxiety and Depression.Psychopharmacology1999, 142(2), 215-220.
Riemann, D. et al. Sleep and Sleep-Wake Manipulations in Bipolar Depression.Neuropsychobiology2002, 45(Suppl. 1), 7-12.
Schlicker, E. et al. Histamine H3 Receptor-Mediated Inhibition of Serotonin Release in the Rat Brain Cortex.Naunyn-Schmiedeberg's Arch. Pharmacol.1988, 337(5), 588-590.
Sharpley, A.L., and P.J. Cowen. Effects of Pharmacologic Treatments on the Sleep of Depressed Patients.Biol. Psych.1995, 37(2), 85-98.
Tomita, T. et al.: Structure-Activity Relationships of Dopamine- and Norepinephrine-Uptake Inhibitors. Chem. Pharm. Bull., vol. 38(6), (1990), 1563-1569. XP 002047151.
Carruthers Nicholas I.
Keith John M.
Letavic Michael A.
Shah Chandravadan R.
Janssen Pharmaceutica N.V.
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Naphthyridine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naphthyridine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naphthyridine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002860